166 related articles for article (PubMed ID: 10721945)
1. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Sadato N; Yonekura Y; Okada K
Jpn J Clin Oncol; 1999 Dec; 29(12):623-9. PubMed ID: 10721945
[TBL] [Abstract][Full Text] [Related]
2. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of prostate cancer using FDG-PET].
Kanamaru H; Oyama N; Akino H; Okada K
Hinyokika Kiyo; 2000 Nov; 46(11):851-3. PubMed ID: 11193311
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
6. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
8. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
10. 11C-acetate PET imaging of prostate cancer.
Oyama N; Akino H; Kanamaru H; Suzuki Y; Muramoto S; Yonekura Y; Sadato N; Yamamoto K; Okada K
J Nucl Med; 2002 Feb; 43(2):181-6. PubMed ID: 11850482
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
12. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.
Han EJ; H O J; Choi WH; Yoo IR; Chung SK
Br J Radiol; 2010 Nov; 83(995):915-20. PubMed ID: 20965901
[TBL] [Abstract][Full Text] [Related]
13. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.
Yi C; Yu D; Shi X; Zhang X; Luo G; He Q; Zhang X
Nucl Med Commun; 2016 Mar; 37(3):239-46. PubMed ID: 26588068
[TBL] [Abstract][Full Text] [Related]
14. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
15. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
16. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
17. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Ishida H; Tanase K; Sadato N; Yonekura Y; Okada K
Nucl Med Commun; 2001 Sep; 22(9):963-9. PubMed ID: 11505204
[TBL] [Abstract][Full Text] [Related]
18. [Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer].
Oyama N; Akino H; Kanamaru H; Okada K
Nihon Rinsho; 1998 Aug; 56(8):2052-5. PubMed ID: 9750506
[TBL] [Abstract][Full Text] [Related]
19. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose.
Effert PJ; Bares R; Handt S; Wolff JM; Büll U; Jakse G
J Urol; 1996 Mar; 155(3):994-8. PubMed ID: 8583625
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
